6533b820fe1ef96bd127a51f
RESEARCH PRODUCT
Frailty and Sarcopenia in Acute‐on‐Chronic Liver Failure
Tommaso Di MairaMarina BerenguerLorena Puchades RenauNatalia Cezón SerranoJulia Herreras LópezMaria ÀNgels Cebrià I IranzoMaria ÀNgels Cebrià I Iranzosubject
medicine.medical_specialtyCirrhosisHepatologybusiness.industryRC799-869ReviewDiseases of the digestive system. Gastroenterologymedicine.diseaseFrailty assessmentUnder nutritionTransplantationSarcopeniamedicineAcute on chronic liver failureIn patientmedicine.symptomIntensive care medicinebusinessWastingdescription
In patients with cirrhosis, sarcopenia is a critical reduction in skeletal muscle mass and frailty represents a status of global physical dysfunction caused by under nutrition, muscle wasting, and functional impairment. Both are prevalent conditions in liver transplant candidates and have shown to be independent predictors of adverse outcome. Evidence supports their incorporation into clinical practice both as a prognostic factor guiding clinical decision making and as a tool to identify candidates for physical and nutritional interventions. The wide heterogeneity of instruments used for sarcopenia and frailty measurement, the absence of a single suitable instrument for sarcopenia and frailty assessment in the outpatient versus inpatient acute‐on‐chronic clinical scenario, and the lack of strong evidence showing a beneficial effect of sarcopenia and frailty improvement on outcomes before and after transplantation are some of the questions that remain unanswered.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2021-08-01 | Hepatology Communications |